ArticleHerz2025
[Diagnosis and treatment of heart failure with reduced ejection fraction].
Article in Herz, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of heart failure with reduced ejection fraction (HFrEF) is based on clinical symptoms, such as peripheral edema or dyspnea and a left ventricular ejection fraction (LVEF) of 40% or less. Treatment is based particularly on the "fantastic four" of renin-angiotensin-aldosterone system (RAAS) inhibitors, preferential angiotensin receptor neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose-linked transporter 2 (SGLT2) inhibitors. These agents have a class I recommendation and show significant benefits in terms of mortality and hospitalization rates. The rapid and complete implementation of the pharmacotherapy substantially improves the prognosis. Additional options, such as ivabradine, vericiguat or digoxin, can be considered if the standard treatment is insufficient. Iron deficiency frequently occurs in HFrEF patients and is associated with increased mortality. Intravenous iron supplementation improves the exercise capacity and reduces hospitalizations.
Indexed as
Identifiers
40601041What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.